Related Experiment Video
Updated: Mar 27, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
A Case of Refractory Polyarticular Juvenile Idiopathic Arthritis Post-hematopoietic Stem Cell Transplantation
Yuta Sonehara1,2, Yuta Maruyama2, Kazuo Sakashita3
1Department of Pediatrics, Nagano Red Cross Hospital, Nagano, JPN.
Abstract:
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may trigger secondary autoimmune diseases, with autoimmune arthritis representing a rare yet challenging complication. Here, we report a six-year-old male who developed polyarticular juvenile idiopathic arthritis (JIA) three years after allo-HSCT for lymphoma. Despite resistance to multiple biologic disease-modifying anti-rheumatic drugs (bDMARDs), including adalimumab and tocilizumab, treatment with the Janus kinase 1/2 inhibitor ruxolitinib achieved clinical remission sustained for over two years without significant adverse events or lymphoma relapse. Ruxolitinib may represent a viable therapeutic option for refractory secondary JIA post-allo-HSCT, particularly when conventional bDMARDs fail.
Related Concept Videos
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Treatment Resistent Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

